Clearside Biomedical (CLSD) Announces Quarterly Earnings Results

Share on StockTwits

Clearside Biomedical (NASDAQ:CLSD) released its earnings results on Thursday. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.12), Fidelity Earnings reports.

Shares of CLSD traded down $0.14 during mid-day trading on Friday, reaching $1.84. The company had a trading volume of 707,532 shares, compared to its average volume of 703,408. Clearside Biomedical has a 1-year low of $1.83 and a 1-year high of $15.33. The company has a current ratio of 7.94, a quick ratio of 7.94 and a debt-to-equity ratio of 0.15. The company has a market cap of $70.13 million, a P/E ratio of -0.79 and a beta of -3.98.

Institutional investors and hedge funds have recently bought and sold shares of the company. Voya Investment Management LLC acquired a new stake in shares of Clearside Biomedical in the 2nd quarter valued at approximately $123,000. Highland Capital Management LLC acquired a new stake in Clearside Biomedical during the 2nd quarter worth approximately $128,000. Cubist Systematic Strategies LLC acquired a new stake in Clearside Biomedical during the 1st quarter worth approximately $132,000. Dynamic Technology Lab Private Ltd acquired a new stake in Clearside Biomedical during the 1st quarter worth approximately $152,000. Finally, Trustcore Financial Services LLC boosted its position in Clearside Biomedical by 280.3% during the 2nd quarter. Trustcore Financial Services LLC now owns 14,585 shares of the company’s stock worth $156,000 after buying an additional 10,750 shares during the period. Institutional investors own 62.23% of the company’s stock.

Several equities analysts have commented on the stock. Laidlaw assumed coverage on shares of Clearside Biomedical in a report on Monday, July 16th. They issued a “buy” rating and a $18.00 target price on the stock. BidaskClub downgraded shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Friday, July 20th. Wedbush set a $29.00 price target on shares of Clearside Biomedical and gave the company a “buy” rating in a research note on Wednesday, August 8th. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. Finally, JPMorgan Chase & Co. downgraded shares of Clearside Biomedical from an “overweight” rating to an “underweight” rating in a research note on Monday, November 5th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Clearside Biomedical presently has a consensus rating of “Hold” and an average target price of $12.71.

TRADEMARK VIOLATION NOTICE: This article was first reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://weekherald.com/2018/11/10/clearside-biomedical-clsd-announces-quarterly-earnings-results.html.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

See Also: Stock Split

Earnings History for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply